His primary areas of investigation include Surgery, Pulmonary embolism, Internal medicine, Randomized controlled trial and Thrombosis. Philip S. Wells interconnects Warfarin and Hazard ratio in the investigation of issues within Surgery. His Pulmonary embolism research integrates issues from Antithrombotic, Predictive value of tests, Radiology, Vascular disease and Venous thrombosis.
His Internal medicine study frequently links to other fields, such as Cardiology. His Randomized controlled trial research is multidisciplinary, relying on both Venous thromboembolism, Clinical trial and Confidence interval. In his research on the topic of Thrombosis, Lost to follow-up, Popliteal vein and Groin is strongly related with Vein.
Philip S. Wells spends much of his time researching Pulmonary embolism, Internal medicine, Surgery, Thrombosis and Venous thrombosis. His Pulmonary embolism research incorporates themes from Venous thromboembolism, Radiology, Pre- and post-test probability, Intensive care medicine and D-dimer. Internal medicine is closely attributed to Cardiology in his study.
Philip S. Wells has researched Surgery in several fields, including Odds ratio and Warfarin. His Thrombosis study integrates concerns from other disciplines, such as Inferior vena cava, Vascular disease, Vein and Risk factor. His work carried out in the field of Randomized controlled trial brings together such families of science as Thrombophilia, Anesthesia and Clinical trial.
Philip S. Wells mostly deals with Internal medicine, Pulmonary embolism, Thrombosis, Venous thromboembolism and Intensive care medicine. Much of his study explores Internal medicine relationship to Surgery. His Pulmonary embolism study combines topics in areas such as Prospective cohort study, Venous thrombosis, Deep vein and Warfarin.
His Thrombosis research is multidisciplinary, relying on both Anesthesia, Randomized controlled trial, Stroke, Atrial fibrillation and Hazard ratio. His Venous thromboembolism research includes elements of Anticoagulant therapy and Major bleeding. He combines subjects such as Oral anticoagulant, Long term risk and Pre- and post-test probability with his study of Intensive care medicine.
Philip S. Wells mainly focuses on Internal medicine, Pulmonary embolism, Thrombosis, Intensive care medicine and Randomized controlled trial. His Internal medicine study frequently draws connections to adjacent fields such as Surgery. Philip S. Wells interconnects Clinical trial and Edoxaban in the investigation of issues within Surgery.
His Pulmonary embolism research is multidisciplinary, incorporating elements of First episode, Lower risk, Prospective cohort study and Deep vein. His work deals with themes such as Anesthesia and Confidence interval, which intersect with Thrombosis. His research in Intensive care medicine intersects with topics in Venous thromboembolism, Venous thrombosis and Anticoagulant therapy.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
Clive Kearon;Elie A. Akl;Anthony J. Comerota;Paolo Prandoni.
Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report
Clive Kearon;Elie A. Akl;Elie A. Akl;Joseph Ornelas;Allen Blaivas.
Derivation of a Simple Clinical Model to Categorize Patients Probability of Pulmonary Embolism: Increasing the Models Utility with the SimpliRED D-dimer
Philip S. Wells;David R. Anderson;Marc Rodger;Jeffrey S. Ginsberg.
Thrombosis and Haemostasis (2000)
Evaluation of D-Dimer in the Diagnosis of Suspected Deep-Vein Thrombosis
Philip S. Wells;David R. Anderson;Marc Rodger;Melissa Forgie.
The New England Journal of Medicine (2003)
A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism.
Clive Kearon;Clive Kearon;Michael Gent;Michael Gent;Jack Hirsh;Jack Hirsh;Jeffrey Weitz.
The New England Journal of Medicine (1999)
Systematic overview of warfarin and its drug and food interactions.
Anne M. Holbrook;Jennifer A. Pereira;Renee Labiris;Heather McDonald.
JAMA Internal Medicine (2005)
Use of a clinical model for safe management of patients with suspected pulmonary embolism.
Philip S. Wells;Jeffrey S. Ginsberg;David R. Anderson;Clive Kearon.
Annals of Internal Medicine (1998)
Comparison of Low-Intensity Warfarin Therapy with Conventional-Intensity Warfarin Therapy for Long-Term Prevention of Recurrent Venous Thromboembolism
Clive Kearon;Jeffrey S. Ginsberg;Michael J. Kovacs;David R. Anderson.
The New England Journal of Medicine (2003)
Risk for heparin-induced thrombocytopenia with unfractionated and low- molecular-weight heparin thromboprophylaxis: a meta-analysis
Nadine Martel;James Lee;Philip S. Wells.
Diagnosis of DVT: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines
Shannon M. Bates;Roman Jaeschke;Scott M. Stevens;Steven Goodacre.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: